Nevro Raises $58M for Anti-Pain Device


Menlo Park, CA-based Nevro, which is developing a neuromodulation device for the treatment of chronic back and leg pain, said yesterday that it has raised $58 million in a Series B financing round led by new investor Johnson & Johnson Development Corporation. Existing investors Aberdare Ventures, Accuitive Medical Ventures, Bay City Capital, Mayo Clinic, MPM Capital, and Three Arch Partners also participated in the round. The startup said the funds will go toward a pivotal clinical study of the device’s effects in the U.S. and help support international commercialization.

Wade Roush is Chief Correspondent and Editor At Large at Xconomy. You can subscribe to his Google Group or e-mail him at Follow @

By posting a comment, you agree to our terms and conditions.